1. ALLA AKTIER
  2. NYHETER
  3. GUARD THERAPEUTICS

Guard Therapeutics

Nyheter Guard Therapeutics Nyheter alla bolag

Guard Therapeutics announces changes in number of shares and votes

MARKN.

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that the number of shares and votes in the Company has changed due to the recently completed Rights Issue (for further information, see the Company’s press release on April 4, 2025).

Through the Rights Issue, the number of shares and votes increased by 7,872,753 shares, amounting to a total of 20,167,631 shares and votes in Guard Therapeutics. External investors who had undertaken to guarantee the Rights Issue chose to receive the guarantee commission in cash.

For further information, please contact:

Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: info@guardtherapeutics.com 

About Guard Therapeutics

Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company’s candidate drugs are based on the endogenous protein alpha-1-microglobulin. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, www.skmg.se.

Attachments

Guard Therapeutics announces changes in number of shares and votes

Datum 2025-04-11, kl 16:30
Källa MFN
Bifogade filer
Guard Therapeutics announces changes in number of shares and votes
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet